Category
Blog
-
2023
-
ACELYRIN acquires ValenzaBio, strengthens immunology position
-
FDA Grants Priority Review to Roche’s Glofitamab BLA in Large B-Cell Lymphoma
-
FDA Approves FoundationOne Liquid CDx to Identify Genomic Profile in NSCLC
-
FDA rejects Biocon insulin biosimilar over data, manufacturing concerns
-
US FDA approves AstraZeneca-Avillion’s asthma treatment Airsupra
-
Australian scientists closer to finding new lung cancer treatments
-
Luye claims its first FDA approval, for bi-weekly schizophrenia drug
-
Hallucination drug could help treat type 2 diabetes
-
FDA Approves Novo Nordisk’s Rybelsus as First Line Treatment for Type 2 Diabetes
-
Oramed’s oral insulin flunks phase 3 diabetes test, sending stock down 70%